OABI earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -4.59. Updated 2026-07-23.
OmniAb (OABI) Research Hub
OmniAb (OABI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.07 USD (+1.50%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.59, market cap 0.25B. This hub links to the full technical, earnings and options research available for OABI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.07 USD (+1.50%) |
| 52-week range | 1.9 USD – 5.08 USD |
| Trend regime | Range |
| 14-day RSI | 65.4 (Bullish) |
| Trailing P/E | -4.59 |
| Market cap | 0.25B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for OABI
Covered Call on OABI: how it works, illustrative setup around the real 4.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OABI: how it works, illustrative setup around the real 4.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OABI: how it works, illustrative setup around the real 4.07 USD price, max profit/loss, breakeven and when to use it. Educational.
OABI technical analysis: range, last 4.07 USD, RSI 65.4, 52w range 1.9 USD–5.08 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OABI in?
OmniAb (OABI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OABI in an uptrend or downtrend?
As of 2026-09-11, OABI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OABI's trailing P/E ratio?
OABI's trailing P/E is -4.59, with a market cap of 0.25B. See the earnings research page for full valuation detail.
When does OABI next report earnings?
OABI is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.11 USD.